Biomedical Engineering Reference
In-Depth Information
156. Akagi, D., et al.,
Biocompatible micellar nanovectors achieve efficient
gene transfer to vascular lesions without cytotoxicity and thrombus
formation.
Gene Ther, 2007.
14
(13): p. 1029-1038.
157. Ofek, P., et al.,
In vivo delivery of small interfering RNA to tumors and
their vasculature by novel dendritic nanocarriers.
FASEB J.
24
(9): p.
3122-3134.
158. Davis, M.E., et al.,
Evidence of RNAi in humans from systemically
administered siRNA via targeted nanoparticles.
Nature.
464
(7291): p.
1067-U140.
159. Greco, F. and M.J. Vicent,
Combination therapy: opportunities and
challenges for polymer-drug conjugates as anticancer nanomedicines.
Adv Drug Deliv Rev, 2009.
61
(13): p. 1203-1213.
160. Vicent, M.J., et al.,
Polymer therapeutics designed for a combination
therapy of hormone-dependent cancer.
Angew Chem Int Ed, 2005.
44
(26): p. 4061-4066.
161. Santucci, L., et al.,
Nitric oxide modulates proapoptotic and antiapoptotic
properties of chemotherapy agents: the case of NO-pegylated epirubicin.
FASEB J., 2006: p. 05-4452fje.
162. Krakovicova, H., T. Etrych, and K. Ulbrich,
HPMA-based polymer
conjugates with drug combination.
Eur J Pharm Sci, 2009.
37
(3-4): p.
405-412.
163. Bae, Y., et al.,
Mixed polymeric micelles for combination cancer
chemotherapy through the concurrent delivery of multiple
chemotherapeutic agents.
J Control Release, 2007.
122
(3): p. 324-
330.
164. Wang, Y., et al.,
Co-delivery of drugs and DNA from cationic core-shell
nanoparticles self-assembled from a biodegradable copolymer.
Nat
Mater, 2006.
5
(10): p. 791-796.
165. Gaspar, R. and R. Duncan,
Polymeric carriers: preclinical safety and
the regulatory implications for design and development of polymer
therapeutics.
Adv Drug Deliv Rev, 2009.
61
(13): p. 1220-1231.
166. Maeda, H.,
Tumor-selective delivery of macromolecular drugs via the
EPR effect: background and future prospects.
Bioconjug Chem, 1992.
21
(5): p. 797-802.
Search WWH ::
Custom Search